1) Li, B., Lu, F., Wei, X., Zhao, R. Fucoidan: structure and bioactivity. Molecules. 13, 1671-1695 (2008).
2) Ohono, M. ed. Biology and technology of economic seaweeds. 1st ed. Uchida Roka- kuho Publishing Co., Ltd. 2004, p297-329. (In Japanese).
3) Hosoda, K. Studies on the components of Naga-kombu, Laminaria longissima-Ⅰ. Bull Japan Soc Sci Fish. 36 (7), 698-701 (1970). (In Japanese).
4) Tako, M., Uehara, M., Kawashima, Y., Chinen, I., Hongo, F. Isolation and identification of fucoidan from Okinawamozuku (Cladosiphon okamuranus Tokida). J Appl Glycosci. 43 (2), 143-148 (1996). (In Japanese)
5) Tanaka, J. ed. Sourui 48 (1). Phycological Res. p13-19 (2000). (Japanese)
6) Kim, S. K. Essentials of Marine Biotechnology. Chapter 6 Seaweed Biotechnology. Springer, Cham, Switzerland, p197-227 (2019).
7) Sakai, T., Kimura, H., Kojima, K., Shimanaka, K., Ikai, K., Kato, I. Marine bacterial sulfated fucoglucuronomannan (SFGM) lyase digests brown algal SFGM into trisaccha- rides. Mar Biotechnol. 5, 70-78 (2003).
8) Lee, J. B., Hayashi, K., Hashimoto, M., Nakano, T., Hayashi, T. Novel antiviral fu- coidan from Sporophyll of Undaria pinnatifida (Mekabu). Chem Pharm Bull. 52 (9), 1091-1094 (2004).
9) Zhao, Y., Zheng, Y., Wang, J., Ma, S., Yu, Y., White, W.L., Yang, S., Yang, F., Lu, J. Fucoidan extracted from Undaria pinnatifida: source for nutraceutical/functional foods. Mar Drugs. 16, 321 (2018).
10) Nagaoka, M., Shibata, H., Kimura-Takagi, I., Hashimoto, S., Kimura, K., Makino, T., Aiyama, R., Ueyama, S., Yokokura, T. Structural study of fucoidan from Cladosiphon okamuranus Tokida. Glycoconj J. 16, 19-26 (1999).
11) Sakai, T., Ishizuka, K., Shimanaka, K., Ikai, K., Kato, I. Structure of oligosaccharides derived from Cladosiphon okamuranus fucoidan by digestion with marine bacteria en- zymes. Mar Biotechnol. 5, 536-544 (2003).
12) Tsuji, M., Sudou, Y., Enoki, M., Tako, M., Konishi, T. Variation in the contents and structure of fucoidan from cultivated Cladosiphon okamuranus Tokida. J Appl Glycosci. 3 (4), 248-252 (2013). (In Japanese)
13) Kido, Y. The issue of nutrition in an aging society. J Nutr Sci Vitaminol. 61, S176- S177 (2015).
14) Annual report on the aging society [summary] FY2020. Cabinet Office Japan. https://www8.cao.go.jp/kourei/english/annualreport/2020/pdf/2020.pdf
15) Nishima, S. Basic act on allergic diseases measures and equalization of medical care in allergic diseases throughout the japan. Allergol Int. 66 (3), 190-203 (2017). (In Japa- nese)
16) Okamura, K. ed. Icones of Japanese algae. Vol. I. Kazama Shobo, 1907, p74-78.
17) Tokida, J. Phycological Observation V. Trans Sapporo Nat Hist Soc. 17 (2), 87-89 (1942).
18) Cumashi, A., Ushakova, N. A., Preobrazhenskaya, M. E., D’Incecco, A., Piccoli, A., Totani, L., Tinari, N., Morozevich, G. E., Berman, A. E., Bilan, M. I., Usov, A. I., Ust- yuzhanina, N. E., Grachev, A. A., Sanderson, C. J., Kelly, M., Rabinovich, G. A., Iacobelli, S., Nifantiev, N. E. A comparative study of the anti-inflammatory, anticoagulant, antian- giogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology. 17 (5), 541-552 (2007).
19) Apostolova, E., Lukova, P., Baldzhieva, A., Katsarov, P., Nikolova, M., Iliev, I., Peychev, L., Trica, B., Oancea, F., Delattre, C., Kokova, V. Immunomodulatory and anti- inflammatory effects of fucoidan: A review. Polymers. 12, 2338 (2020).
20) Ustyuzhanina, N. E., Ushakova, N. A., Zyuzina, K. A., Bilan, M. I., Elizarova, A. L., Somonova, O. V., Madzhuga, A. V., Krylov, V. A., Preobrazhenskaya, M. E., Usov, A. I., Kiselevskiy, M. V., Nifantiev, N. E. Influence of fucoidans on hemostatic system. Mar Drugs.11, 2444-2458 (2013).
21) Liu, F., Wang, J., Chang, A. K., Liu, B., Yang, L., Li, Q., Wang, P., Zou, X. Fucoidan extract derived from Undaria pinnatifida inhibits angiogenesis by human umbilical vein endothelial cells. Phytomedicine. 19, 797-803 (2012).
22) Atashrazm, F., Lowenthal, R. M., Woods, G. M., Holloway, A. F., Dickinson, J. L. Fucoidan and cancer: a multifunctional molecule with anti-tumor potential. Mar Drugs. 13, 2327-2346 (2015).
23) Lin, Y., Qi, X., Liu, H., Xue, K., Xu, S., Tian, Z. The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations. Cancer Cell Int. 20 (1), 154 (2020).
24) Aleissa, M. S., Alkahtani, S., Eldaim, M. A. A., Ahmed, A. M., Bungau, S. G., Almu- tairi, B., Bin-Jumah, M., Alkahtane, A. A., Alyousif, M. S., Abdel-Daim M. M. Fucoidan ameliorates oxidative stress, inflammation, DNA damage, and hepatorenal injuries in di- abetic rats intoxicated with aflatoxin B1. Oxid Med Cell Longev. 2020. doi.org/10.1155/2020/9316751.
25) Azuma, K., Ishihara, T., Nakamoto, H., Amaha, T., Osaki, T., Tsuka, T., Imagawa, T., Minami, S., Takashima, O., Ifuku, S., Morimoto, M., Saimoto, H., Kawamoto, H., Oka- moto, Y. Effects of oral administration of fucoidan extracted from Cladosiphon okamura- nus on tumor growth and survival time in a tumor-bearing mouse model. Mar Drugs. 10, 2337-2348 (2012).
26) Hidari, K. I., Takahashi, N., Arihara, M., Nagaoka, M., Morita, K., Suzuki, T. Struc- ture and anti-dengue virus activity of sulfated polysaccharide from marine alga. Biochem Biophys Res Comm. 376, 91-95 (2008).
27) Shibata, H., Iimuro, M., Uchiya, N., Kawamori, T., Nagaoka, M., Ueyama, S., Hash- imoto, S., Yokokura, T., Sugimura, T., Wakabayashi, K. Preventive effects of Cladosiphon fucoidan against Helicobacter pylori infection in Mongolian gerbils. Helicobacter. 8, 59- 65 (2003).
28) Suzuki, T., Yamamoto, Y., Onuki, J., Hirano, M., Shibuya, F., Nagaoka, M., Hash- imoto, S., Yokokura, T. Experience with intravenous bolus injection of iopamidol for hel- ical computed tomography (CT). Jpn Pharmacol Ther. 28 (11), 931-935 (2000). (In Jap- anese)
29) Tomori, M., Matsuda, K., Nakamura, Y., Kadena, K., Shimoji, S., Nagamine, T., Iha, M. Effect of Cladosiphon okamuranus fucoidan containing drink on improvement of def- ecation in healthy subjects with mild constipation. -A randomized, double-blind, placebo- controlled, crossover study-. Jpn Pharmacol Ther. 44 (11), 1621-1626 (2016). (In Japa- nese)
30) Nagamine, T., Kadena, K., Tomori, M., Nakajima, K., Iha, M. Activation of NK cells in male cancer survivors by fucoidan extracted from Cladosiphon okamuranus. Mol Clin Oncol. 12, 81-88 (2020).
31) Ikeda-Ohtsubo, W., Nadal, A. L., Zaccaria, E., Iha, M., Kitazawa, H., Kleerebezem, M., Brugman, S. Intestinal microbiota and immune modulation in Zebrafish by fucoidan from Okinawa mozuku (Cladosiphon okamuranus). Front Nutr. 7 (67) (2020). doi: 10.3389/fnut.2020.00067.
32) Tokita, Y., Nakajima, K., Mochida, H., Iha, M., Nagamine, T. Development of a fucoidan-specific antibody and measurement of fucoidan in serum and urine by sandwich ELISA. Biosci Biotechnol Biochem. 74 (2), 350-357 (2010).
33) Nakazato, K., Takada, H., Iha, M., Nagamine, T. Attenuation of N-nitrosodiethyla- mine-induced liver fibrosis by high-molecular-weight fucoidan derived from Cladosi- phon okamuranus. J Gastroenterol Hepatol. 25, 1692-1701 (2010).
34) Nagamine, T., Nakazato, K., Tomioka, S., Iha, M., Nakajima, K. Intestinal absorption of fucoidan extracted from the brown seaweed, Cladosiphon okamuranus. Mar Drugs. 13, 48-64 (2015).
35) Kadena, K., Tomori, M., Iha, M., Nagamine, T. Absorption study of Mozuku fucoidan in Japanese volunteers. Mar Drugs. 16, 254 (2018).
36) Takeuchi, H., Trang, V., Morimoto, N., Nishida, Y., Matsumura, Y., Sugiura, T. Natu- ral products and food components with anti-Helicobacter pylori activities. World J Gas- troenterol. 20 (27), 8971-8978 (2014).
37) Matsumoto, S., Nagaoka, M., Hara, T., Kimura-Takagi, I., Mitsuyama, K., Ueyama, S. Fucoidan derived from Cladosiphon okamuranus Tokita ameliorates murine chronic colitis through the down-regulation of interleukin-6 production on colonic epithelial cells. Clin Exp Immunol. 136, 432-439 (2004).
38) McClure, M. O., Whitby, D., Patience, N., Gooderham, N. J., Bradshaw, A., Popov, R. C., Weber, J. N, Davies, D. S., Cook, G. M. W., Keynes, R. J., Weiss, R. A. Dextrin sulfate and fucoidan are potent inhibitors of HIV infection in vitro. Antivir Chem Chemother. 2, 149-156 (1991).
39) Nagamine, T., Hayakawa, K., Kusakabe, T., Takada, H., Nakazato, K., Hisanaga, E., Iha, M. Inhibitory effect of fucoidan on Huh7 hepatoma cells through downregulation of CXCL12. Nutr Cancer. 61, 340-347 (2009).
40) Ikeguchi, M., Saito, H., Miki, Y., Kimura, T. Effect of fucoidan dietary supplement on the chemotherapy treatment of patients with unresectable advanced gastric cancer. J Cancer Ther. 6, 1020-1026 (2015).
41) Ohnogi, H., Naito, Y., Higashimaru, Y., Uno, K., Yoshikawa, T. Immune efficacy and safety of fucoidan extracted from Gagome Kombu (Kjellmaniella crassifolia) in healthy Japanese subjects. Jpn J Complement Altern Med. 12, 87-93 (2015).
42) Murayama, H., Tamauchi, H., Hashimoto, M., Nakano, T. Suppression of Th2 im- mune responses by Mekabu fucoidan from Undaria pinnatifida sporophylls. Int Arch Al- lergy Immunol. 137, 289-294 (2005).
43) Nishitsuji, K., Arimoto, A., Iwai, K., Sudo, Y., Hisata, K., Fujie, M., Arakaki, N., Kushiro, T., Konishi, T., Shinzato, C., Satoh, N., Shoguchi, E. A draft genome of the brown alga, Cladosiphon okamuranus, S-strain: a platform for future studies of “mozuku” biology. DNA Res. 23 (6), 561-570 (2016).
44) Shibata, H., Kimura-Takagi, I., Nagaoka, M., Hashimoto, S., Sawada, H., Ueyama, S., Yokokura, T. Inhibitor effect of Cladosiphon fucoidan on the adhesion of Helicobacter pylori to human gastric cells. J Nutr Sci Vitaminol. 45, 325-336 (1999).
45) Nagaoka, M., Shibata, H., Kimura-Takagi, I., Hashimoto, S., Aiyama, R., Ueyama, S., Yokokura, T. Anti-ulcer effects and biological activities of polysaccharides from ma- rine algae. Biofactors 2000, 12, 267-274.
46) Yamamoto, Y., Suzuki, T., Hirano, M., Nagaoka, M., Hashimoto, S., Shibata, H., Ki- mura-Takagi, I., Ueyama, S., Kudo, T., Yoshikawa, M., Yokokura, T. Effect of fucoidan and fucoidan containing tea on gastric ulcer and non-ulcer dyspepsia. Jpn Pharmacol Ther. 28 (1), 63-70 (2000). (In Japanese)
47) Chen, Y., Tsai, Y., Tsai, T., Chiu, Y., Wei, L., Chen, W., Huang, C. Fucoidan supplementation improves exercise performance and exhibits anti-fatigue action in mice. Nutrients. 7, 239-252 (2015).
48) Abe, S., Hiramatsu, K., Ichikawa, O., Ikeda, T., Kawamoto, H., Kasagi, T., Miki, Y. Effects of Mozuku fucoidan on defecation and fecal condition in human. J Yonago Med Assoc. 61, 122-128 (2010). (In Japanese)
49) Haneji, K., Matsuda, T., Tomita, M., Kawakami, H., Ohshiro, K., Uchihara, J., Ma- suda, M., Takasu, N., Tanaka, Y., Ohta, T., Mori, N. Fucoidan extracted from Cladosiphon okamuranus Tokida induces apoptosis of human T-cell leukemia virus type 1-infected T- cell lines and primary adult T-cell leukemia cells. Nutr Cancer. 52 (2), 189–201 (2005).
50) Araya, N., Takahashi, K., Sato, T., Nakamura, T., Sawa, C., Hasegawa, D., Ando, H., Aratani, S., Yagishita, N., Fujii, R., Oka, H., Nishioka, K., Nakajima, T., Mori, N., Ya- mano, Y. Fucoidan therapy decreases the proviral load in patients with human T-lympho- tropic virus type-1-associated neurological disease. Antivir Ther. 16, 89–98 (2011).
51) Guidance for Industory. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2005.
52) Irhimeh, M. R., Fitton, J. H., Lowenthal, R. M., Kongtawelert, P. A quantitative method to detect fucoidan in human plasma using a novel antibody. Methods Find Exp Clin Pharmacol. 27 (10), 705–710 (2005).
53) Murayama, H., Tamauchi, H., Iizuka, M., Nakano, T. The role of NK cells in anti- tumor activity of dietary fucoidan from Undaria pinnatifida Sporophylls (Mekabu). Planta Med. 72, 1415–1417 (2006).
54) Tokita, Y., Hirayama, M., Nakajima, K., Tamaki, K., Iha, M., Nagamine, T. Detection of fucoidan in urine after oral intake of traditional Japanese seaweed, Okinawa Mozuku (Cladosiphon okamuranus Tokida). J Nutr Sci Vitaminol. 63, 419-421 (2017).
55) Shimizu, J., Wada-Funada, U., Mano, H., Matahira, Y., Kawaguchi, M., Wada, M. Proportion of murine cytotoxic T cells is increased by high molecular-weight fucoidan extracted from Okinawa Mozuku (Cladosipohn okamuranus). J Health Sci. 51(3), 394- 397 (2005).
56) Jang J., Moon, S., Joo, H. Differential effects of fucoidans with low and high molec- ular weight on the viability and function of spleen cells. Food Chem Toxicol. 68, 234-238 (2014).
57) Doi, T., Higashino, K., Kurihara, Y., Wada, Y., Miyazaki, T., Nakamura, H., Uesugi, S., Imanishi, T., Kawabe, Y., Itakura, H., Yazaki, Y., Matsumoto, A., Kodama, T. Charged collagen structure mediates the recognition of negatively charged macromolecules by macrophage scavenger receptors. J Biol Chem. 268 (3), 2126-2133 (1993).
58) Takai, M., Miyazaki, Y., Tachibana, H., Yamada, K. The enhancing effect of fucoidan derived from Undaria pinnatifida on immunoglobulin production by mouse spleen lym- phocytes. Biosci Biotechnol Biochem. 78 (10), 1743-1747 (2014).
59) Mori, N, Nakasone, K, Tomimori, K, Ishikawa, C. Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection. World J Gastroenterol. 18 (18), 2225- 2230 (2018).
60) Choi, J., Raghavendran, H., Sung, N., Kim, J., Chun, B., Ahn, D., Choi, H., Kang, K., Lee, J. Effect of fucoidan on aspirin-induced stomach ulceration in rats. Chem Biol Inter- act. 183, 249-254 (2010).
61) Abe, S., Hiramatsu, K., Ichikawa, O., Kawamoto, H., Kasagi, T., Miki, Y., Kimura, T., Ikeda, T. Safety evaluation of excessive ingestion of Mozuku fucoidan in human. J Food Sci. 78 (4), T648-T651 (2013).
62) Tomori, M., Nagamine, T., Miyamoto, T., Iha, M. Evaluation of the immunomodula- tory effects of fucoidan derived from Cladosiphon okamuranus Tokida in mice. Mar Drugs. 17, 547 (2019).
63) Negishi, H., Mori, M., Mori, H., Yamori, Y. Supplementation of elderly Japanese men and women with fucoidan from seaweed increases immune responses to seasonal influ- enza vaccination. J Nutr. 2013, 143, 1794-1798.
64) Takahashi, H., Kawaguchi, M., Kitamura, K., Narumiya, S., Kawamura, M., Tengan, I., Nishimoto, S., Hanamure, Y., Majima, Y., Tsubura, S., Teruya, K., Shirahata, S. An exploratory study on the anti-inflammatory effects of fucoidan in relation to quality of life in advanced cancer patients. Integr Cancer Ther. 17 (2), 282–291 (2018).
65) Zhang, W., Okimura, T., Oda, T., Jin, J. Ascophyllan induces activation of natural killer cells in mice in vivo and in vitro. Mar Drugs. 17, 197 (2019).
66) Lin, Z., Tan, X., Zhang, Y., Li, F., Luo, P., Liu, H. Molecular targets and related bio- logic activities of fucoidan: A review. Mar Drugs. 18, 376 (2020).
67) Miyazaki, Y., Iwaihara, Y., Bak, J., Nakano, H., Takeuchi, S., Takeuchi, H., Matsui, T., Tachikawa, D. The cooperative induction of macrophage activation by fucoidan de- rived Cladosiphon okamuranus and β-glucan derived from Saccharomyces cerevisiae. Biochem Biophys Res Commun. 516, 245-250 (2019).
68) Klein, S. L., Flanagan, K. L. Sex differences in immune responses. Nat Rev Immunol. 16, 626-638 (2016).
69) Pisitkun, P., Deane, A. J., Difilippantonio, M. J., Tarasenko, T., Satterthwaite, A. B., Bolland, S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 312, 1669-1672 (2006).
70) Ngo, S. T., Steyn, F. J., McCombe, P. A. Gender differences in autoimmune disease. Front Neuroendocrinol. 35, 347-369 (2014).
71) Namkoong, S., Kim, Y., Kim, T., Sohn, E. Immunomodulatory effects of fucoidan on NK cells in ovariectomized rats. Korean J Plant Res. 25 (3), 317-322 (2012).
72) Tomori, M., Hirata, T., Nagamine, T., Iha, M. Safety evaluation of long-term and excessive ingestion of Cladosiphon okamuranus fucoidan in healthy subjects. A random- ized, double-blind, placebo-controlled, parallel study. Jpn Pharmacol Ther. 45 (3), 447- 461 (2017). (In Japanese)
73) Wu, L., Sun, J., Su, X., Yu, Q., Yu, Q., Zhang, P. A review about the development of fucoidan in antitumor activity: progress and challenges. Carbohydr Polym. 154, 96-111 (2016).
74) Fitton, J. H., Stringer, D. N., Park, A., Karpiniec, S. S. Therapies from fucoidan: new developments. Mar Drugs. 17, 571 (2019).
75) Weelden, G. van., Bobinski, M., Okla, K., Weelden, W. Jan. van., Romano, A., Pijnen- borg, J. M. A. Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms. Mar Drugs. 2019, 17, 32.
76) Wang, Y., Xing, M., Cao, Q., Ji, A., Liang, H., Song, S. Biological activities of fu- coidan and the factors mediating its therapeutic effects: a review of recent studies. Mar Drugs. 17, 183 (2019).
77) Besednova, N. N., Zaporozhets, T. S., Somova, L. M., Kuznetsova, T. A. Prospects for the use of extracts and polysaccharides from marine algae to prevent and treat the diseases caused by Helicobacter Pylori. Helicobacter. 20, 89-97 (2015).
78) Chua, E., Verbrugghe, P., Perkins, T. T., Tay, C. Fucoidan disrupt adherence of Heli- cobacter pylori to AGS cells in vitro. Evid Based Complement Alternat Med. 2015. doi.org/10.1155/2015/120981
79) Nagamine, T., Hayakawa, K., Nakazato, K., Iha, M. Determination of the active transport of fucoidan derived from Okinawa Mozuku across the human intestinal Caco-2 cells as assessed by size-exclusion chromatography. J Chromatogr B. 997, 187-193 (2015).
80) Zhang, E., Chu, F., Xu, L., Liang, H., Song, S., Ji, A. Use of fluorescein isothiocyanate isomer Ⅰ to study the mechanism of intestinal absorption of fucoidan sulfate in vivo and in vitro. Biopharm Drug Dispos. 39 (6), 298-307 (2018).
81) Imbs, T. I., Zvyagintseva, T. N., Ermakova, S. P. Is the transformation of fucoidans in human body possible? Int J Biol Macromol. 142, 778-781 (2020).
82) Hehemann, J. H., Correc, G., Barbeyron, T., Helbert, W., Czjzek, M., Michel, G. Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota. Nature. 464, 908-914 (2010).
83) Sipponen, P., Helske, T., Järvinen, P., Hyvärinen, H., Seppälä, K., Siurala, M. Fall in the prevalence of chronic gastritis over 15 years: analysis of outpatient series in Finland from 1977, 1985, and 1992. Gut. 35, 1167-1171 (1994).
84) Kamada, T., Haruma, K., Ito, M., Inoue, K., Manabe, N., Matsumoto, H., Kusunoki, H., Hata, J., Yoshihara, M., Sumii, K., Akiyama, T., Tanaka, S., Shiotani, A., Graham, D. Y. Time trends in Helicobacter pylori infection and atrophic gastritis over 40 years in Japan. Helicobacter. 20 (3),192‐198 (2015).
85) Pichon, M., Burucoa, C. Impact of the gastro-intestinal bacterial microbiome on Hel- icobacter-associated diseases. Healthcare. 7, 34 (2019).
86) Pero, R., Brancaccio, M., Laneri, S., Biasi M. G. De., Lombardo, B., Scudiero, O. A novel view of human Helicobacter pylori infections: interplay between microbiota and beta-defensins. Biomolecules. 9, 237 (2019).
87) Franceschi, F., Annalisa, T., Teresa, D. R., Giovanna, D., Ianiro, G., Franco, S., Vivi- ana, G., Valentina, T., Riccardo, L. L., Antonio, G. Role of Helicobacter pylori infection on nutrition and metabolism. World J Gastroenterol. 20 (36), 12809-12817 (2014).
88) Aditi, A., Graham, D. Y. Vitamin C, gastritis, and gastric disease: a historical review and update. Dig Dis Sci. 57, 2504-2515 (2012).
89) Akcam, M. Helicobacter pylori and micronutrients. Indian Pediatr. 47 (2), 119-126 (2010).
90) Kato, M., Asaka, M., Saito, M., Sekine, H., Ohara, S., Toyota, T., Akamatsu, T., Kaneko, T., Kiyosawa, K., Nishizawa, O., Kumagai, T., Katsuyama, T., Abe, M., Kosaka, M., Hariya, S., Minami, K., Sanai, Y., Sawamura, M., Tachikawa, T. Clinical usefulness of urine-based enzyme-linked immunosorbent assay for detection of antibody to Helico- bacter pylori: a collaborative study in nine medical institutions in Japan. Helicobacter. 5 (2), 109-119 (2000).
91) Miwa, H., Hirose, M., Kikuchi, S., Terai, T., Iwazaki, R., Kobayashi, O., Takei, Y., Ogihara, T., Sato, N. How useful is the detection kit for antibody to Helicobacter pylori in urine (URINELISA) in clinical practice? Am J Gastroenterol. 94 (12), 3460-3463 (1999).
92) Katsuragi, K., Noda, A., Tachikawa, T., Azuma, A., Mukai, F., Murakami, K., Fujioka, T., Kato, M., Asaka, M. Highly sensitive urine-based enzyme-linked immunosorbent as- say for detection of antibody to Helicobacter pylori. Helicobacter. 3 (4), 289-295 (1998).
93) Amornlerdpison, D., Peerapornpisal, Y., Taesotikul, T., Noiraksar, T., Kanjanapothi, D. Gastroprotective activity of Padina minor Yamada. Chiang Mai J Sci. 36 (1), 92–103 (2009).
94) Biesalski, H. K. Nutrition meets the microbiome: micronutrients and the microbiota. Ann N.Y Acad Sci. 1372 (1), 53-64 (2016).
95) Ticinesi, A., Lauretani, F., Milani, C., Nouvenne, A., Tana, C., Rio, D. D., Maggio, M., Ventura, M., Meschi, T. Aging gut microbiota at the cross-road between nutrition, physical frailty, and sarcopenia: Is there a gut-muscle axis? Nutrients. 9, 1303 (2017).
96) Sandhu, K. V., Sherwin, E., Schellekens, H., Stanton, C., Dinan, T. G., Cryan, J. F. Feeding the microbiota-brain axis: diet, microbiome, and neuropsychiatry. Transl Res. 179:223-244 (2017).
97) Valdes, A. M., Walter, J, Segal, E., Spector, T. D. Role of the gut microbiota in nutri- tion and health. BMJ. 361, k2179 (2018).
98) Moschen, A. R., Wieser, V., Tilg, H. Dietary factors: major regulators of the gut’s microbiota. Gut Liver. 6 (4), 411-416 (2012).
99) Das, A., Pereira, V., Saxena, S., Ghosh, T. S., Anbumani, D., Bag, S., Das, B., Nair, B., Abraham, P., Mande, S. S. Gastric microbiome of indian patients with Helicobacter pylori infection, and their interaction networks. Sci Rep. 7, 15438 (2017).
100) Maldonado-Contreras, A., Goldfarb, K. G., Godoy-Vitorino, F., Karaoz, U., Contre- ras, M., Blaser, M. J., Brodie, E. J., Dominguez-Bello, M. G. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J. 5 (4), 574- 579 (2011).
101) Schulz, C., Schütte, K., Koch, N., Vilchez-Vargas, R., Wos-Oxley, M. L., Oxley, A. P. A., Vital, M., Malfertheiner, P., Pieper, D. H. The active bacterial assemblages of the upper GI tract in individuals with and without Helicobacter infection. Gut. 67, 216-225 (2018).
論文の公開元へ
